Cover Image
市場調查報告書

寡核甘酸合成的全球市場:各產品·各零件·提供方式·各終端用戶·各地區 - 市場規模·佔有率·趨勢、成長率·需求的預測

Oligonucleotide Synthesis Market by Offering, by Application, by End User, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013 - 2023

出版商 P&S Market Research Pvt. Ltd 商品編碼 666074
出版日期 內容資訊 英文 177 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
寡核甘酸合成的全球市場:各產品·各零件·提供方式·各終端用戶·各地區 - 市場規模·佔有率·趨勢、成長率·需求的預測 Oligonucleotide Synthesis Market by Offering, by Application, by End User, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013 - 2023
出版日期: 2018年06月01日 內容資訊: 英文 177 Pages
簡介

本報告提供全球合成寡核甘酸的市場相關分析,提供技術概要和市場結構,主要的推動及阻礙市場要素,市場規模的實際成果值·預測值 (過去5年·今後6年份),產品/各類服務·各用途·各終端用戶及地區別詳細趨勢,市場競爭狀態,主要企業簡介等調查。

第1章 分析的背景情況

第2章 分析方法

第3章 摘要整理

第4章 簡介

  • 市場區隔定義
    • 各產品與服務
      • 合成寡核甘酸
        • 各產品
        • 各類服務
      • 試劑·消耗品
      • 各種設備
    • 各用途
      • 研究
        • PCR
        • qPCR
        • 定序
        • 遺傳基因合成
        • 其他
      • 診斷
      • 治療
        • RNAi
        • 核酸核酸適體
        • DNA/反義寡核甘酸 (ASO)
        • 免疫療法用
    • 各終端用戶
      • 教育·研究機關
      • 診斷測試室
      • 製藥·生物科技企業
      • 其他
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 波特的五力分析

第5章 全球市場:市場規模與其預測

  • 各產品
    • 合成寡核甘酸市場:各類型
      • 產品市場
      • 服務市場
  • 各用途
    • 研究目的用
    • 治療目的用
  • 各終端用戶
  • 各地區/各國

第6章 北美市場:市場規模與其預測

第7章 歐洲市場:市場規模與其預測

第8章 亞太地區市場:市場規模與其預測

第9章 南美市場:市場規模與其預測

第10章 中東·非洲市場:市場規模與其預測

第11章 競爭環境

  • 主要企業的產品的互相比較
  • 主要企業的策略部署情形
    • 企業合併·收購 (M&A)
    • 產品銷售
    • 事業聯盟
    • 其他

第12章 企業簡介

  • Eurofins Scientific SE
    • 產業概要
    • 主要產品與服務
    • 主要的財務指標
  • LGC Limited
  • Danaher Corporation
  • GeneDesign Inc.
  • Maravai LifeSciences Inc.
  • Kaneka Eurogentec S.A.
  • General Electric Company
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Genscript Biotech Corporation

第13章 附錄

目錄

Based on offering, the oligonucleotide synthesis market is classified into synthesized oligonucleotides, reagents and consumables, and equipment. During the historical period, synthesized oligonucleotides held the largest share in the market, accounting for 76.3% in 2017.

Based on application, the oligonucleotide synthesis market is categorized into research, diagnostics, and therapeutics. Of these, the fastest growth in the market during the forecast period is expected from research applications, with a CAGR of 11.1%.

On the basis of end user, the market is categorized into academic research institutes, diagnostic laboratories, pharmaceutical and biotechnology companies, and others. Others primarily include food and beverage companies and forensic laboratories. Academic research institutes are expected to continue holding the largest share in the oligonucleotide synthesis market in the coming years. They accounted for 40.4% share in the market in 2017.

Geographically, North America held the largest share in oligonucleotide synthesis, with 39.1% contribution in 2017. This can be attributed to technological advancements, favorable government regulations, and high incidence of infectious diseases in the region.

During the forecast period, the oligonucleotide synthesis market is projected to witness the fastest growth in APAC, with a CAGR of 11.6%. The market growth in the region can be attributed to improving healthcare infrastructure, increasing need for better health outcomes, and rising prevalence of chronic and infectious diseases.

Rising geriatric population is also driving the growth of the oligonucleotide synthesis market in APAC. According to the UN publication World Population Ageing 2017, more than 962 million people were aged 60 years or above in 2017, globally, which is more than double the number of the people aged 60 years or above in 1980 (382 million). By 2050, this population is expected to double, to reach 2.1 billion.

According to the UN publication, the number of the Japanese aged 80 years or above was 9 million in 2013, and it is expected to reach 17 million by 2050. In addition, 23.2% of Japanese population aged over 60 years in 2000, and it is expected to reach 35% by 2025.

In order to increase their market share, key players of the oligonucleotide synthesis industry are seeking partnerships and acquisitions. For instance, in May 2018, LGC Biosearch Technologies Inc. (LGC) acquired BioAutomation Corporation (BioAutomation), a manufacturer of MerMade oligo synthesis instruments. The acquisition followed LGC's acquisitions of Biosearch, Prime Synthesis, and LINK Technologies, and is expected to further drive the company's growth in the oligonucleotide reagent and synthesized oligonucleotide markets.

In March 2018, Thermo Fisher Scientific Inc. (Thermo Fisher), acquired IntegenX Inc., a provider of rapid DNA platforms for use in forensics and law enforcement applications. IntegenX products have significantly enhanced Thermo Fisher's existing human identification (HID) portfolio and complemented its leading human identification chemistries, and qPCR and capillary electrophoresis systems.

Some of the other key players operating in the oligonucleotide synthesis industry are General Electric Company, Merck KGaA, Eurofins Scientific SE, Integrated DNA Technologies Inc., GeneDesign Inc., Trilink Biotechnologies LLC, and Kaneka Eurogentec S.A.

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Offering
    • 1.3.2 Market Segmentation by Application
    • 1.3.3 Market Segmentation by End User
    • 1.3.4 Market Segmentation by Geography
    • 1.3.5 Analysis Period
    • 1.3.6 Market Data Reporting Unit
      • 1.3.6.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Offering
      • 4.1.1.1 Synthesized oligonucleotides
        • 4.1.1.1.1 By products
        • 4.1.1.1.1.1 Primers
        • 4.1.1.1.1.2 Probes
        • 4.1.1.1.1.3 Large-scale synthesis oligonucleotides
        • 4.1.1.1.1.4 Intermediate-scale synthesis oligonucleotides
        • 4.1.1.1.1.5 Linkers and adaptors
        • 4.1.1.1.2 By services
        • 4.1.1.1.2.1 Custom oligonucleotides
        • 4.1.1.1.2.2 Pre-designed oligonucleotides
      • 4.1.1.2 Reagents and consumables
      • 4.1.1.3 Equipment
    • 4.1.2 By Application
      • 4.1.2.1 Research
        • 4.1.2.1.1 Polymerase chain reaction (PCR)
        • 4.1.2.1.2 Quantitative polymerase chain reaction (qPCR)
        • 4.1.2.1.3 Sequencing
        • 4.1.2.1.4 Gene synthesis
        • 4.1.2.1.5 Others
      • 4.1.2.2 Diagnostics
      • 4.1.2.3 Therapeutics
        • 4.1.2.3.1 RNAi
        • 4.1.2.3.2 Nucleic acid aptamers
        • 4.1.2.3.3 DNA/antisense oligonucleotides
        • 4.1.2.3.4 Immunotherapy applications
    • 4.1.3 By End User
      • 4.1.3.1 Academic research institutes
      • 4.1.3.2 Diagnostic laboratories
      • 4.1.3.3 Pharmaceutical and biotechnology companies
      • 4.1.3.4 Others
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
      • 4.2.1.1 Technological advancements in oligonucleotide synthesis products
      • 4.2.1.2 Increasing support from government organizations
      • 4.2.1.3 Increasing research activities in synthetic biology
      • 4.2.1.4 Increasing burden of cancer and infectious diseases
      • 4.2.1.5 Impact analysis of drivers on market forecast
    • 4.2.2 Restraints
      • 4.2.2.1 Stringent regulatory requirements
      • 4.2.2.2 Lack of techniques for large-scale synthesis of oligonucleotide
      • 4.2.2.3 Impact analysis of restraints on market forecast
    • 4.2.3 Opportunities
      • 4.2.3.1 Growing focus on personalized medicine
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Buyers
    • 4.3.2 Bargaining Power of Suppliers
    • 4.3.3 Intensity of Rivalry
    • 4.3.4 Threat of New Entrants
    • 4.3.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

  • 5.1 By Product
    • 5.1.1 Synthesized Oligonucleotides Market by Type
      • 5.1.1.1 Synthesized oligonucleotides products market by type
      • 5.1.1.2 Synthesized oligonucleotides services market by type
  • 5.2 By Application
    • 5.2.1 Oligonucleotide Synthesis Market for Research by Type
    • 5.2.2 Oligonucleotide Synthesis Market for Therapeutics by Type
  • 5.3 By End User
  • 5.4 By Region

Chapter 6. North America Market Size and Forecast

  • 6.1 By Product
    • 6.1.1 Synthesized Oligonucleotides Market by Type
      • 6.1.1.1 Synthesized oligonucleotides products market by type
      • 6.1.1.2 Synthesized oligonucleotides services market by type
  • 6.2 By Application
    • 6.2.1 Oligonucleotide Synthesis Market for Research by Type
    • 6.2.2 Oligonucleotide Synthesis Market for Therapeutics by Type
  • 6.3 By End User
  • 6.4 By Country

Chapter 7. Europe Market Size and Forecast

  • 7.1 By Product
    • 7.1.1 Synthesized Oligonucleotides Market by Type
      • 7.1.1.1 Synthesized oligonucleotides products market by type
      • 7.1.1.2 Synthesized oligonucleotides services market by type
  • 7.2 By Application
    • 7.2.1 Oligonucleotide Synthesis Market for Research by Type
    • 7.2.2 Oligonucleotide Synthesis Market for Therapeutics by Type
  • 7.3 By End User
  • 7.4 By Country

Chapter 8. APAC Market Size and Forecast

  • 8.1 By Offering
    • 8.1.1 Synthesized Oligonucleotides Market by Type
      • 8.1.1.1 Synthesized oligonucleotides products market by type
      • 8.1.1.2 Synthesized oligonucleotides services market by type
  • 8.2 By Application
    • 8.2.1 Oligonucleotide Synthesis Market for Research by Type
    • 8.2.2 Oligonucleotide Synthesis Market for Therapeutics by Type
  • 8.3 By End User
  • 8.4 By Country

Chapter 9. LATAM Market Size and Forecast

  • 9.1 By Offering
    • 9.1.1 Synthesized Oligonucleotides Market by Type
      • 9.1.1.1 Synthesized oligonucleotides products market by type
      • 9.1.1.2 Synthesized oligonucleotides services market by type
  • 9.2 By Application
    • 9.2.1 Oligonucleotide Synthesis Market for Research by Type
    • 9.2.2 Oligonucleotide Synthesis Market for Therapeutics by Type
  • 9.3 By End User
  • 9.4 By Country

Chapter 10. MEA Market Size and Forecast

  • 10.1 By Offering
    • 10.1.1 Synthesized Oligonucleotides Market by Type
      • 10.1.1.1 Synthesized oligonucleotides products market by type
      • 10.1.1.2 Synthesized oligonucleotides services market by type
  • 10.2 By Application
    • 10.2.1 Oligonucleotide Synthesis Market for Research by Type
    • 10.2.2 Oligonucleotide Synthesis Market for Therapeutics by Type
  • 10.3 By End User
  • 10.4 By Country

Chapter 11. Competitive Landscape

  • 11.1 Product Benchmarking of Key Players
  • 11.2 Global Strategic Developments of Key Players
    • 11.2.1 Mergers and Acquisitions
    • 11.2.2 Product Launches
    • 11.2.3 Partnerships
    • 11.2.4 Other Developments

Chapter 12. Company Profiles

  • 12.1 Eurofins Scientific SE
    • 12.1.1 Business Overview
    • 12.1.2 Product and Service Offerings
    • 12.1.3 Key Financial Summary
  • 12.2 LGC Limited
    • 12.2.1 Business Overview
    • 12.2.2 Product and Service Offerings
    • 12.2.3 Key Financial Summary
  • 12.3 Danaher Corporation
    • 12.3.1 Business Overview
    • 12.3.2 Product and Service Offerings
    • 12.3.3 Key Financial Summary
  • 12.4 GeneDesign Inc.
    • 12.4.1 Business Overview
    • 12.4.2 Product and Service Offerings
  • 12.5 Maravai LifeSciences Inc.
    • 12.5.1 Business Overview
    • 12.5.2 Product and Service Offerings
  • 12.6 Kaneka Eurogentec S.A.
    • 12.6.1 Business Overview
    • 12.6.2 Product and Service Offerings
  • 12.7 General Electric Company
    • 12.7.1 Business Overview
    • 12.7.2 Product and Service Offerings
    • 12.7.3 Key Financial Summary
  • 12.8 Thermo Fisher Scientific Inc.
    • 12.8.1 Business Overview
    • 12.8.2 Product and Service Offerings
    • 12.8.3 Key Financial Summary
  • 12.9 Merck KGaA
    • 12.9.1 Business Overview
    • 12.9.2 Product and Service Offerings
    • 12.9.3 Key Financial Summary
  • 12.10 Genscript Biotech Corporation
    • 12.10.1 Business Overview
    • 12.10.2 Product and Service Offerings
    • 12.10.3 Key Financial Summary

Chapter 13. Appendix

  • 13.1 Abbreviations
  • 13.2 Sources and References
  • 13.3 Related Reports

LIST OF TABLES

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 NUMBER OF MORTALITIES DUE TO VARIOUS DISEASES, GLOBALLY
  • TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 4 NIH GUIDELINES IN THE U.S., BY EXPERIMENT TYPE
  • TABLE 5 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 6 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2017)
  • TABLE 7 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2018-2023)
  • TABLE 8 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 9 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 10 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE $M (2013-2017)
  • TABLE 11 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2018-2023)
  • TABLE 12 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 13 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 14 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2017)
  • TABLE 15 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2018-2023)
  • TABLE 16 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2017)
  • TABLE 17 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2018-2023)
  • TABLE 18 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2013-2017)
  • TABLE 19 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2018-2023)
  • TABLE 20 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2017)
  • TABLE 21 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2018-2023)
  • TABLE 22 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, $M (2013-2017)
  • TABLE 23 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, $M (2018-2023)
  • TABLE 24 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2017)
  • TABLE 25 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2018-2023)
  • TABLE 26 NORTH AMERICA SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 27 NORTH AMERICA SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 28 NORTH AMERICA SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE $M (2013-2017)
  • TABLE 29 NORTH AMERICA SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2018-2023)
  • TABLE 30 NORTH AMERICA SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 31 NORTH AMERICA SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 32 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2017)
  • TABLE 33 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2018-2023)
  • TABLE 34 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2017)
  • TABLE 35 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2018-2023)
  • TABLE 36 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2013-2017)
  • TABLE 37 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY, $M (2018-2023)
  • TABLE 38 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2017)
  • TABLE 39 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2018-2023)
  • TABLE 40 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2017)
  • TABLE 41 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2018-2023)
  • TABLE 42 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2017)
  • TABLE 43 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2018-2023)
  • TABLE 44 EUROPE SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 45 EUROPE SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 46 EUROPE SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE $M (2013-2017)
  • TABLE 47 EUROPE SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2018-2023)
  • TABLE 48 EUROPE SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 49 EUROPE SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 50 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2017)
  • TABLE 51 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2018-2023)
  • TABLE 52 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2017)
  • TABLE 53 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2018-2023)
  • TABLE 54 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2013-2017)
  • TABLE 55 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BYTYPE, $M (2018-2023)
  • TABLE 56 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2017)
  • TABLE 57 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2018-2023)
  • TABLE 58 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2017)
  • TABLE 59 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2018-2023)
  • TABLE 60 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2017)
  • TABLE 61 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2018-2023)
  • TABLE 62 APAC SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 63 APAC SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 64 APAC SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2013-2017)
  • TABLE 65 APAC SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2018-2023)
  • TABLE 66 APAC SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 67 APAC SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 68 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2017)
  • TABLE 69 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2018-2023)
  • TABLE 70 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2017)
  • TABLE 71 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2018-2023)
  • TABLE 72 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2013-2017)
  • TABLE 73 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2018-2023)
  • TABLE 74 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2017)
  • TABLE 75 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2018-2023)
  • TABLE 76 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2017)
  • TABLE 77 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2018-2023)
  • TABLE 78 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2017)
  • TABLE 79 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2018-2023)
  • TABLE 80 LATAM SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 81 LATAM SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 82 LATAM SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2013-2017)
  • TABLE 83 LATAM SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2018-2023)
  • TABLE 84 LATAM SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 85 LATAM SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 86 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2017)
  • TABLE 87 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2018-2023)
  • TABLE 88 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2017)
  • TABLE 89 LATAM OLIGONUCLEOTIDE SYNTHESIS FOR RESEARCH MARKET, BY TYPE, $M (2018-2023)
  • TABLE 90 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2013-2017)
  • TABLE 91 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2018-2023)
  • TABLE 92 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2017)
  • TABLE 93 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2018-2023)
  • TABLE 94 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2017)
  • TABLE 95 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2018-2023)
  • TABLE 96 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2017)
  • TABLE 97 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2018-2023)
  • TABLE 98 MEA SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 99 MEA SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 100 MEA SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2013-2017)
  • TABLE 101 MEA SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2018-2023)
  • TABLE 102 MEA SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2017)
  • TABLE 103 MEA SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2018-2023)
  • TABLE 104 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2017)
  • TABLE 105 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2018-2023)
  • TABLE 106 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2017)
  • TABLE 107 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2018-2023)
  • TABLE 108 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS MARKET, BY TYPE, $M (2013-2017)
  • TABLE 109 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2018-2023)
  • TABLE 110 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2017)
  • TABLE 111 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2018-2023)
  • TABLE 112 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2017)
  • TABLE 113 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2018-2023)
  • TABLE 114 EUROFINS SCIENTIFIC SE - AT A GLANCE
  • TABLE 115 EUROFINS SCIENTIFIC SE - KEY FINANCIAL SUMMARY
  • TABLE 116 LGC LIMITED - AT A GLANCE
  • TABLE 117 LGC LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 118 DANAHER CORPORATION - AT A GLANCE
  • TABLE 119 DANAHER CORPORATION - KEY FINANCIAL SUMMARY
  • TABLE 120 GENEDESIGN INC. - AT A GLANCE
  • TABLE 121 MARAVAI LIFESCIENCES INC. - AT A GLANCE
  • TABLE 122 KANEKA EUROGENTEC S.A. - AT A GLANCE
  • TABLE 123 GENERAL ELECTRIC COMPANY - AT A GLANCE
  • TABLE 124 GENERAL ELECTRIC COMPANY - KEY FINANCIAL SUMMARY
  • TABLE 125 THERMO FISHER SCIENTIFIC INC. - AT A GLANCE
  • TABLE 126 THERMO FISHER SCIENTIFIC INC. - KEY FINANCIAL SUMMARY
  • TABLE 127 MERCK KGAA - AT A GLANCE
  • TABLE 128 MERCK KGAA - KEY FINANCIAL SUMMARY
  • TABLE 129 GENSCRIPT BIOTECH CORPORATION - AT A GLANCE
  • TABLE 130 GENSCRIPT BIOTECH CORPORATION - KEY FINANCIAL SUMMARY

LIST OF FIGURES

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 7 DATA TRIANGULATION APPROACH
  • FIG 8 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SUMMARY
  • FIG 9 PORTER'S FIVE FORCES ANALYSIS
  • FIG 10 SNAPSHOT OF GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET (2017)
  • FIG 11 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2023)
  • FIG 12 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2023)
  • FIG 13 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2023)
  • FIG 14 WORLDWIDE MAJOR MARKETS FOR OLIGONUCLEOTIDE SYNTHESIS
  • FIG 15 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIG 16 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2023)
  • FIG 17 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2023)
  • FIG 18 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2023)
  • FIG 19 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2023)
  • FIG 20 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIG 21 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2023)
  • FIG 22 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2023)
  • FIG 23 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2023)
  • FIG 24 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2023)
  • FIG 25 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIG 26 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2023)
  • FIG 27 APAC SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2023)
  • FIG 28 APAC SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2013-2023)
  • FIG 29 APAC SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2023)
  • FIG 30 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2023)
  • FIG 31 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2023)
  • FIG 32 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2013-2023)
  • FIG 33 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2023)
  • FIG 34 APAC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2023)
  • FIG 35 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIG 36 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2023)
  • FIG 37 LATAM SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2023)
  • FIG 38 LATAM SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2013-2023)
  • FIG 39 LATAM SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2023)
  • FIG 40 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2023)
  • FIG 41 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2023)
  • FIG 42 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTICS, BY TYPE, $M (2013-2023)
  • FIG 43 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2023)
  • FIG 44 LATAM OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2023)
  • FIG 45 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIG 46 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, $M (2013-2023)
  • FIG 47 MEA SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, $M (2013-2023)
  • FIG 48 MEA SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS MARKET, BY TYPE, $M (2013-2023)
  • FIG 49 MEA SYNTHESIZED OLIGONUCLEOTIDES SERVICES MARKET, BY TYPE, $M (2013-2023)
  • FIG 50 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, $M (2013-2023)
  • FIG 51 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH, BY TYPE, $M (2013-2023)
  • FIG 52 MEA OLIGONUCLEOTIDE SYNTHESIS FOR THERAPEUTICS MARKET, BY APPLICATION, $M (2013-2023)
  • FIG 53 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, $M (2013-2023)
  • FIG 54 MEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, $M (2013-2023)
  • FIG 55 PRODUCT BENCHMARKING OF KEY PLAYERS
  • FIG 56 EUROFINS SCIENTIFIC SE - REVENUE SPLIT BY GEOGRAPHY (2017)
  • FIG 57 DANAHER CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 58 GENERAL ELECTRIC COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 59 THERMO FISHER SCIENTIFIC INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 60 MERCK KGAA - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 61 GENSCRIPT BIOTECH CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
Back to Top